Elevación del índice neutrófilo/linfocito y su relación con la proteína C reactiva en pacientes con diabetes mellitus tipo 2
DOI:
https://doi.org/10.47196/diab.v55i3.474Palabras clave:
diabetes, inflamación, índice neutrófilo/linfocitoResumen
La diabetes mellitus (DM) es una enfermedad metabólica caracterizada por hiperglucemia, la cual ocurre como consecuencia de defectos en la acción de la insulina sobre su receptor, en la secreción de insulina o en ambas. La hiperglucemia crónica se asocia con daño, disfunción e insuficiencia a largo plazo de diferentes órganos, especialmente ojos, riñones, nervios, corazón y vasos sanguíneos. Es una enfermedad que ha alcanzado proporciones epidémicas. La última edición del Atlas de la Federación Internacional de Diabetes (FID) muestra que 463 millones de adultos viven actualmente con DM y se estima que habrá 578 millones de adultos con DM para el año 2030 y 700 millones para 2045. La prevalencia de DM (en adultos de 20-79 años) en América Central y América del Sur fue de 8,5% en 2019 y se prevé que para 2030 será de 9,5 y de 9,9% para el año 2045.
Citas
I. American Diabetes Association. Classification and diagnosis of diabetes. Standards of Medical Care in Diabetes 2021. Diabetes Care Jan 2021; 44 (Supplement 1) S15-S33.
II. International Diabetes Federation. Revisado: 10 enero de 2021. Disponible en http://www.idf.org/diabetesatlas.
III. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375:2215-2222.
IV. García C, Feve B, Ferré P, Halimi S, Baizri H, Bordier L, et al. Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab 2010; 36:327-338.
V. Shiny A, Bibin YS, Shanthirani CS, Regin BS, Anjana RM, Balasubramanyam M, et al. Association of neutrophil-lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. Diabetes Technol Ther 2014; 16:524-530.
VI. Balta S, Celik T, Mikhailidis DP, Ozturk C, Demirkol S, Aparci M, et al. The relation between atherosclerosis and the neutrophil-lymphocyte ratio. Clin Appl Thromb Hemost 2016; 22:405-411.
VII. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24:325-331.
VIII. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
IX. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
X. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014; 105:141-150.
XI. DiGangi C. Neutrophil-lymphocyte ratio: predicting cardiovascular and renal complications in patients with diabetes. J Am Assoc Nurse Pract 2016; 28:410-414.
XII. Wang J, Zhu QW, Cheng XY, Sha CX, Cui YB. Clinical significance of neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in women with hyperglycemia. Postgrad Med 2020; 132:702-708.
XIII. Li J, Li T, Wang H, Yan W, Mu Y. Neutrophil-lymphocyte ratio as a predictor of kidney function decline among individuals with diabetes and prediabetes: A 3-year follow-up study. J Diabetes 2019; 11:427-430.
XIV. Verdoia M, Schaffer A, Barbieri L, Aimaretti G, Marino P, Sinigaglia F, et al. Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. Diabetes Metab 2015; 41:304-311.
XV. Wan H, Wang Y, Fang S, Chen Y, Zhang W, Xia F, et al. Associations between the neutrophil-to-lymphocyte ratio and diabetic complications in adults with diabetes. A cross-sectional study. J Diabetes Res 2020; 1-9.
XVI. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279:48487-48490.
XVII. Pitsavos C, Tampourlou M, Panagiotakos DB, Skoumas Y, Chrysohoou C, Nomikos T, et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and qomen from the ATTICA Study. Rev Diabet Stud 2007; 4:98-104.
XVIII. Shiwaku K, Anuurad E, Enkhmaa B, Nogi A, Kitajima K, Shimono K, et al. Overweight Japanese with body mass indexes of 23.0-24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. International Journal of Obesity and Related Metabolic Disorders 2004; 28 (1):152-158.
XIX. Ryder E, Pedreañez A, Vargas R, Peña C, Fernández E, Diez-Ewald M, et al. Increased proinflammatory markers and lipoperoxidation in obese individuals. Inicial inflammatory events? Diabetes Metab Syndr 2015 Oct-Dec; 9(4):280-6.
XX. Ryder E, Diez-Ewald M, Mosquera J, Fernández E, Pedreañez A, Vargas R, et al. Association of obesity with leukocyte count in obese individuals without metabolic syndrome. Diabetes Metab Syndr 2014 Oct-Dec; 8(4):197-204.
XXI. Vargas R, Ryder E, Diez-Ewald M, Mosquera J, Durán A, Valero N, et al. Increased C-reactive protein and decreased Interleukin-2 content in serum from obese individuals with or without insulin resistance. Associations with leukocyte count and insulin and adiponectin content. Diabetes Metab Syndr 2016 Jan-Mar; 10(1 Suppl 1):S34-41.
XXII. Yilmaz H, Ucan B, Sayki M, Unsal I, Sahin M, Ozbek M, et al. Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity. Diabetes Metab Syndr 2015 Oct-Dec; 9(4):299-304.
XXIII. Iglesias-Molli AE, Bergonzi MF, Spalvieri MP, Linari MA, Frechtel GD, Cerrone GE. Relationship between the IL-1β serum concentration, mRNA levels and rs16944 genotype in the hyperglycemic normalization of T2D patients. Sci Rep 2020 Jun 19; 10(1):9985.
XXIV. Byun K, Yoo Y, Son M, Lee J, Jeong GB, Park YM, Salekdeh GH, Lee B. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacol Ther 2017 Sep; 177:44-55.
XXV. Gibson PH, Cuthbertson BH, Croal BL, Rae D, El-Shafei H, Gibson G, et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010; 105:186-191.
XXVI. Sawant AC, Adhikari P, Narra SR, Srivatsa SS, Mills PK, Srivatsa SS. Neutrophil to lymphocyte ratio predicts short- and long-term mortality following revascularization therapy for ST elevation myocardial infarction. Cardiology Journal 2014; 21:500-508.
XXVII. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. The American Journal of Cardiology 2008;102:653–657.
XXVIII. Azab B, Chainani V, Shah N, McGinn JT. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4-year follow-up study. Angiology 2013; 64:456-465.
XXIX. Azab B, Daoud J, Naeem FB, Nasr R, Ross J, Ghimire P, et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Ren Fail 2012; 34:571-576.
XXX. Mertoglu C, Gunay M. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr 2016; 11:127-131.
XXXI. Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 1992; 10:267-293.
XXXII. Jailer JW, Marks DT, Marks PA. Variations in white blood cells following the oral administration of glucose to diabetics and nondiabetics. J Clin Endocrinol Metab 1948; 8:1074-1080.
XXXIII. Xu H, Chen Y, Li Y, Xia F, Han B, Zhang H, et al. Mitochondrial apoptosis of lymphocyte is induced in type 2 diabetes. Chin Med J (Engl) 2014; 127:213-217.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Diabetes.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
